Showing results (351-360 of 392) with videos related to
Sort By:
Pageof 40
The New England Journal of Medicine|June 6, 2019
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ConditionsKirsten Fischer, Othman Al-Sawaf, Jasmin Bahlo, et al.Nature|October 16, 2015
Mutations driving CLL and their evolution in progression and relapseDan A Landau, Eugen Tausch, Amaro N Taylor-Weiner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2024
End Point Surrogacy in First-Line Chronic Lymphocytic LeukemiaFlorian Simon, Rudy Ligtvoet, Sandra Robrecht, et al.Blood|September 4, 2025
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trialFlorian Simon, Rudy Ligtvoet, Jan-Paul Bohn, et al.Haematologica|January 18, 2015
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic LeukemiaCarol Moreno, Marco Montillo, Panayiotis Panayiotidis, et al.Blood|April 16, 2025
International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC RecommendationsAdam S Kittai, Monia Marchetti, Othman Al-Sawaf, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2024
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 TrialPetra Langerbeins, Sandra Robrecht, Pascal Nieper, et al.Lancet (London, England)|June 18, 2016
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Eva Hoster, Jan Walewski, et al.Blood|April 6, 2023
Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemiaQu Jiang, Johanna Stachelscheid, Johannes Bloehdorn, et al.Nature Communications|September 14, 2021
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemiaJohannes Bloehdorn, Andrejs Braun, Amaro Taylor-Weiner, et al.Pageof 40